stockrow
Saturday 7 November 2026
Export OABI’s income statement to Excel — free account
OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024.
- Revenue
- +78.3%
- EPS
- +14.3%
- Free cash flow
- +206.3%
Quarter to September 2026, against a year earlier
5.02
0.19
+3.93%
Follow OABI
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
15.95 | 8.24 | 6.96 | 11.26 | |
P/FCF ratio |
269.46 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
60.64 | 118.27 | (40.97) | (37.05) | |
P/B ratio |
2.57 | 1.22 | 0.77 | 0.79 | |
Price to Tangible BV |
12.29 | 5.26 | 3.38 | 3.63 | |
EV/Sales |
14.35 | 6.89 | 5.26 | 8.37 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
216.46 | (14.99) | (5.97) | (4.28) | |
EV/FCF |
242.48 | (14.60) | (6.61) | (4.59) | |
Quick Ratio |
3.96 | 4.53 | 4.55 | 3.78 | |
Current Ratio |
4.21 | 4.80 | 4.80 | 4.02 | |
Net Debt/EBITDA |
5.20 | 20.28 | 60.29 | 6.51 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.13 | 0.13 | 0.10 | 0.06 | |
Operating CF/Net income |
(0.67) | (0.46) | 0.64 | 0.40 | |
Capex/Depreciation |
0.00 | (0.03) | (0.02) | 0.00 | |
Research and Development Expense of Revenue |
239.24% | 71.46% | 66.82% | 166.06% | |
Selling, General and Administrative Expense of Revenue |
181.42% | 49.59% | 45.88% | 81.65% | |
Intangible Assets out of Total Assets |
0.68 | 0.69 | 0.69 | 0.70 | |
Share Based Compensation of Revenue |
76.58% | 23.55% | 23.15% | 43.05% | |
Graham Net Nets |
0.05 | 0.11 | 0.17 | 0.15 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.85%) | (14.63%) | (29.30%) | (30.81%) | |
Free Cash Flow Yield |
0.37% | (5.73%) | (11.43%) | (16.18%) | |
Revenue per Share |
0.03 | 0.10 | 0.11 | 0.07 | |
Operating CF per Share |
0.08 | 0.02 | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.08 | 0.02 | (0.04) | (0.05) | |
Cash per Share |
0.50 | 0.40 | 0.38 | 0.48 | |
Shareholders Equity per Share |
1.93 | 2.02 | 2.05 | 2.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.93 | 2.02 | 2.05 | 2.35 | |
Free Cash Flow |
10.58 | 2.57 | (5.08) | (5.68) | |
Working Capital |
54.13 | 52.26 | 51.56 | 49.09 | |
Capital Expenditures |
0.00 | (0.11) | (0.17) | (0.01) | |
Net Current Asset Value |
29.22 | 36.03 | 34.12 | 31.45 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.83 | 6.52 | 9.56 | 6.33 | |
Average Payables |
1.66 | 2.03 | 1.79 | 2.09 | |
Average Assets |
300.31 | 292.97 | 299.92 | 313.24 | |
Average Common Equity |
263.30 | 261.17 | 268.08 | 277.32 |
Columns are period end dates · fundamentals updated 6 Nov 2026